OBJECTIVE: This study aims to analyze gender differences in patients with prolactinomas who were operated on transsphenoidal surgery and conduct a single-center retrospective analysis of patient data.
METHODS: This study evaluated the medical records of 109 patients (61 females and 48 males) from 2009 to 2019 at Feofaniya Clinical Hospital of the State Administration of Affairs in Kyiv, Ukraine. The primary criterion for including patients was a Serum Prolactin (PRL) level of over 100 ng/ml and the presence of a pituitary adenoma (PA) as observed on MRI. Additionally, the histological examination needed to confirm the presence of Prolactin-Secreting Pituitary Adenomas (PSPAs) without plurihormonal activity through both microscopy and immunohistochemical (IHC) staining.
RESULTS: Significant differences in preoperative PRL levels were not observed. However, males had significantly larger tumor sizes and prevalence of macroadenomas. In male patients, the preoperative PLR levels showed a weak negative correlation with age (r=-0.304, p < 0.036) and a positive correlation with tumor size (r=0.555, p < 0.001) and cavernous sinus invasion (r=0.339, p < 0.018). In females, preoperative PRL was significantly associated only with tumor size and Knosp grade.
CONCLUSIONS: Prolactin-Secreting Pituitary Adenomas (PSPAs) are more common in women than men and are characterized by larger and more invasive tumors with high PRL levels at diagnosis. The PRL level and tumor size before surgery can predict early biochemical remission in both males and females with an accuracy of 58.3% and 68.8%, respectively.
目的:本研究旨在分析经蝶入路手术的泌乳素瘤患者的性别差异,并对患者数据进行单中心回顾性分析。
方法:本研究评估了2009年至2019年在基辅国家事务管理局Feofaniya临床医院的109例患者(女61例,男48例)的病历,乌克兰。包括患者的主要标准是血清催乳素(PRL)水平超过100ng/ml,并且在MRI上观察到存在垂体腺瘤(PA)。此外,需要进行组织学检查,以通过显微镜和免疫组织化学(IHC)染色确认分泌催乳素的垂体腺瘤(PSPAs)的存在,而无多种激素活性.
结果:未观察到术前PRL水平的显著差异。然而,男性有明显更大的肿瘤大小和大腺瘤的患病率。在男性患者中,术前PLR水平与年龄(r=-0.304,p<0.036)呈弱负相关,与肿瘤大小(r=0.555,p<0.001)和海绵窦侵犯(r=0.339,p<0.018)呈正相关。在女性中,术前PRL仅与肿瘤大小和Knosp分级显著相关。
结论:泌乳素分泌型垂体腺瘤(PSPAs)在女性中比男性更常见,其特征是在诊断时具有高PRL水平的更大、更侵袭性的肿瘤。术前的PRL水平和肿瘤大小可以预测男性和女性的早期生化缓解,准确率分别为58.3%和68.8%,分别。